ARCT to seek Q4 go/no-go for CF inhaled mRNA Phase III
ARCT said Q4 will bring a go/no-go decision on advancing its cystic fibrosis inhaled mRNA therapy to Phase III, alongside imminent Phase II data and OTC deficiency program regulatory updates. The plan cites a $40M Thermo Fisher agreement.
The conference highlighted imminent phase II data and regulatory updates for the OTC deficiency program, along with a Q4 go/no-go decision on advancing the cystic fibrosis inhaled mRNA therapy to phase III, supported by a unique $40M Thermo Fisher agreement. AI is playing an expanding role in R&D.